← Leaderboards
Patrick Robert Griffin
Exsar Corporation
$27,944,167
Attributed
$37,779,127
Total exposure
24
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,779,127 · 24
By mechanism
R01$23,570,194 · 11
U54$6,614,379 · 4
U19$2,868,860 · 1
UH3$1,763,827 · 1
P50$1,446,628 · 1
UH2$762,851 · 2
Top collaborators
- Theodore M Kamenecka16 shared
- Courtney A Miller7 shared
- Beata Anna Lecka-Czernik6 shared
- Jorge Plutzky5 shared
- Pere Puigserver5 shared
- Dean P Edwards4 shared
- Raj Kumar4 shared
- Paul J Kenny1 shared
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeBaseCellsReceptorProteinsAgonistProgramsDeuteriumPropertyResponsePharmacologyDesignInsightIn VivoHydrogenLeadPromoterPharmaceutical PreparationsComplexLigandsLiverIn VitroNuclear ReceptorsReporting
Grant awards (77)
PPARG regulates osteocyte bioenergetics and function during aging$668,560
R01 · FY2025 · AG
Structural dynamics of progesterone receptor-coactivator complexes$608,524
R01 · FY2025 · CA · contact PI
Quantifying and modeling ligand-dependent control of RORγ dynamics via structural proteomics$592,836
R01 · FY2025 · DK · contact PI
PPARG regulates osteocyte bioenergetics and function during aging$682,204
R01 · FY2024 · AG
Structural dynamics of progesterone receptor-coactivator complexes$578,099
R01 · FY2024 · CA · contact PI
Quantifying and modeling ligand-dependent control of RORγ dynamics via structural proteomics$569,122
R01 · FY2024 · DK · contact PI
PPARG regulates osteocyte bioenergetics and function during aging$665,558
R01 · FY2023 · AG
Small molecules targeting hepatic glucose production and insulin resistance$650,222
R01 · FY2023 · DK
Structural dynamics of progesterone receptor-coactivator complexes$596,710
R01 · FY2023 · CA · contact PI
Quantifying and modeling ligand-dependent control of RORγ dynamics via structural proteomics$592,836
R01 · FY2023 · DK · contact PI
PPARG regulates osteocyte bioenergetics and function during aging$687,185
R01 · FY2022 · AG
Small molecules targeting hepatic glucose production and insulin resistance$656,218
R01 · FY2022 · DK
Structural dynamics of progesterone receptor-coactivator complexes$655,489
R01 · FY2022 · CA · contact PI
Quantifying and modeling ligand-dependent control of RORγ dynamics via structural proteomics$592,836
R01 · FY2022 · DK · contact PI
HDX and NMR Core$1,045,733
U54 · FY2021 · AI · contact PI
PPARG regulates osteocyte bioenergetics and function during aging$678,086
R01 · FY2021 · AG
Small molecules targeting hepatic glucose production and insulin resistance$656,218
R01 · FY2021 · DK
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2021 · DK
PPARG regulates osteocyte bioenergetics and function during aging$26,388
R56 · FY2021 · AG
Small molecules targeting hepatic glucose production and insulin resistance$656,218
R01 · FY2020 · DK
HDX and NMR Core$514,709
U54 · FY2020 · AI · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2020 · DK
Developing nonmuscle II inhibitors for substance use relapse$90,459
UH3 · FY2020 · NS
Small molecules targeting hepatic glucose production and insulin resistance$661,093
R01 · FY2019 · DK
Molecular Characterization of Novel Insulin Sensitizers$582,733
R01 · FY2019 · DK · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2019 · DK
HDX and NMR Core$285,472
U54 · FY2019 · AI · contact PI
Developing nonmuscle II inhibitors for substance use relapse$180,291
UH3 · FY2019 · NS
Developing nonmuscle II inhibitors for substance use relapse$90,459
UH3 · FY2019 · NS
Developing nonmuscle II inhibitors for substance use relapse$631,712
UH3 · FY2018 · NS
Molecular Characterization of Novel Insulin Sensitizers$582,733
R01 · FY2018 · DK · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2018 · DK
Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer$439,200
R01 · FY2018 · CA · contact PI
Optimization of ERRg-specific ligands as in vivo Chemical Probes$398,400
R01 · FY2018 · HD
HDX and NMR Core$283,358
U54 · FY2018 · GM · contact PI
Developing nonmuscle II inhibitors for substance use relapse$148,694
UH3 · FY2018 · NS
Developing nonmuscle II inhibitors for substance use relapse$622,212
UH3 · FY2017 · NS
Molecular Characterization of Novel Insulin Sensitizers$582,733
R01 · FY2017 · DK · contact PI
ALDH1a1 Inhibition As A Therapeutic Target In Visceral Adiposity and Type 2 Diabetes$490,000
R01 · FY2017 · DK
Development of RORbeta-selective modulators as in vivo probes$480,000
R01 · FY2017 · MH · contact PI
Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer$439,200
R01 · FY2017 · CA · contact PI
Optimization of ERRg-specific ligands as in vivo Chemical Probes$398,400
R01 · FY2017 · HD
HDX and NMR Core$294,671
U54 · FY2017 · GM · contact PI
Developing nonmuscle II inhibitors for substance use relapse$638,362
UH2 · FY2016 · NS
Molecular Characterization of Novel Insulin Sensitizers$582,733
R01 · FY2016 · DK · contact PI
Development of RORbeta-selective modulators as in vivo probes$480,000
R01 · FY2016 · MH · contact PI
Optimization of RORgamma-specific agonists as immune activators for a new immunotherapy approach for cancer$439,200
R01 · FY2016 · CA · contact PI
Optimization of ERRg-specific ligands as in vivo Chemical Probes$398,400
R01 · FY2016 · HD
Project 10$291,396
P50 · FY2016 · GM · contact PI
Molecular Characterization of Novel Insulin Sensitizers$605,733
R01 · FY2015 · DK · contact PI
Development of RORbeta-selective modulators as in vivo probes$480,000
R01 · FY2015 · MH · contact PI
Project 10$269,969
P50 · FY2015 · GM · contact PI
Funct character of GABA_B receptor modulators, drug metabolism, pharmacokinetics$603,509
U19 · FY2014 · DA · contact PI
Project 10$291,770
P50 · FY2014 · GM · contact PI
Funct character of GABA_B receptor modulators, drug metabolism, pharmacokinetics$575,406
U19 · FY2013 · DA · contact PI
Project 10$284,018
P50 · FY2013 · GM · contact PI
Funct character of GABA_B receptor modulators, drug metabolism, pharmacokinetics$595,276
U19 · FY2012 · DA · contact PI
Development of HTS assays to discover modulators of LRH-1$398,525
R01 · FY2012 · CA · contact PI
Development of H/D exchange technology for the study of large protein complexes$397,823
R01 · FY2012 · GM · contact PI
Project 10$309,475
P50 · FY2012 · GM · contact PI
Funct character of GABA_B receptor modulators, drug metabolism, pharmacokinetics$554,200
U19 · FY2011 · DA · contact PI
Center Based Initiative #2 (Florida)$518,458
U54 · FY2011 · MH · contact PI
Development of HTS assays to discover modulators of LRH-1$398,525
R01 · FY2011 · CA · contact PI
Development of H/D exchange technology for the study of large protein complexes$390,791
R01 · FY2011 · GM · contact PI
Scripps Florida Product Development Partnership for smoking cessation therapeutic$124,489
UH2 · FY2011 · DA · contact PI
Center Based Initiative #2 (Florida)$1,072,582
U54 · FY2010 · MH · contact PI
Funct character of GABA_B receptor modulators, drug metabolism, pharmacokinetics$540,469
U19 · FY2010 · DA · contact PI
Acquisition of a LTQ/Orbitrap MS to advance the study of protein dynamics$499,950
S10 · FY2010 · RR · contact PI
Development of HTS assays to discover modulators of LRH-1$403,588
R01 · FY2010 · CA · contact PI
Development of H/D exchange technology for the study of large protein complexes$394,738
R01 · FY2010 · GM · contact PI
Center Based Initiative #3 (Florida)$692,014
U54 · FY2009 · MH · contact PI
Selectivity/Spec Profiling (Florida)$610,844
U54 · FY2009 · MH · contact PI
Development of H/D exchange technology for the study of large protein complexes$398,725
R01 · FY2009 · GM · contact PI
Center Based Initiative #3 (Florida)$687,893
U54 · FY2008 · MH · contact PI
Selectivity/Spec Profiling (Florida)$608,645
U54 · FY2008 · MH · contact PI
Protein Binding Sites by Computational Screening &HD-Ex$93,750
R43 · FY2004 · GM
Mapping the M2 Proton Channel by H/D-LC-MS$132,300
R43 · FY2003 · GM